Travere Therapeutics, Inc. (TVTX) Form 10-Q — Nov 2, 2026
Travere Therapeutics' Q3 2026 revenue jumped 36% to $224.6 million, driven by FILSPARI sales more than doubling year-over-year to $200.2 million following the April 2026 FDA approval of FILSPARI as the first approved treatment for FSGS. Despite the top-line strength, the company posted a quarterly net loss of $52.3 million versus net income of $25.7 million a year ago, primarily due to a one-time $113.1 million in-process R&D charge for the Everest Medicines civorebrutinib license, which carries a $112.5 million upfront and up to $1.0 billion in milestones.
Key figures
- Revenue
- 224563000
- Total Debt
- 603510000
- Revenue Yoy
- +36% Q3 ($224.6M vs $164.9M); nine-month revenue $521.3M vs $361.0M
- Total Assets
- 848229000
- Cash Position
- 471818000
- Shares Outstanding
- 95992155
- 2032 notes coupon
- 0.50%
- Q3 filspari sales
- 200192000
- 2032 notes principal
- 525000000
- Iprd expense everest
- 113115000
- Q3 filspari growth yoy
- +120% ($200.2M vs $90.9M)
- Everest upfront payment
- 112500000
- Induced conversion expense
- 40008000
- Everest milestones potential
- 1000000000
- Mirum milestone recognized q3
- 10000000
- 2029 notes remaining principal
- 94875000
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.